{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formoterol+fumarate+%2812+%CE%BCg%29&page=2",
    "query": {
      "intervention": "Formoterol fumarate (12 μg)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formoterol+fumarate+%2812+%CE%BCg%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formoterol+fumarate+%2812+%CE%BCg%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T01:04:23.317Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01444430",
      "title": "A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Symbicort pMDI",
          "type": "DRUG"
        },
        {
          "name": "budesonide pMDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "12 Years to 130 Years"
      },
      "enrollment_count": 12460,
      "start_date": "2011-12",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2016-12-15",
      "last_synced_at": "2026-10-10T01:04:23.317Z",
      "location_count": 160,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01444430"
    },
    {
      "nct_id": "NCT02796677",
      "title": "AMPLIFY - D6571C00001 Duaklir USA Phase III Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)",
          "type": "DRUG"
        },
        {
          "name": "Aclidinium bromide 400 μg (AB 400 μg)",
          "type": "DRUG"
        },
        {
          "name": "Formoterol fumarate 12 μg (FF 12 μg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg",
          "type": "OTHER"
        },
        {
          "name": "Tiotropium 18 μg (TIO 18 μg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to TIO 18 μg",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "40 Years to 130 Years"
      },
      "enrollment_count": 1595,
      "start_date": "2016-07-05",
      "completion_date": "2017-06-08",
      "has_results": true,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-10-10T01:04:23.317Z",
      "location_count": 85,
      "location_summary": "Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more",
      "locations": [
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02796677"
    },
    {
      "nct_id": "NCT01085045",
      "title": "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT003 MDI",
          "type": "DRUG"
        },
        {
          "name": "PT005 MDI",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDI",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium bromide 18 μg (Spiriva Handihaler®)",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Fumarate 12 μg (Foradil® Aerolizer®)",
          "type": "DRUG"
        },
        {
          "name": "PT001 MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 118,
      "start_date": "2010-03",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-10-10T01:04:23.317Z",
      "location_count": 4,
      "location_summary": "Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01085045"
    },
    {
      "nct_id": "NCT01349803",
      "title": "PT003 MDI Cardiovascular Safety Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT005 MDI",
          "type": "DRUG"
        },
        {
          "name": "PT001 MDI",
          "type": "DRUG"
        },
        {
          "name": "PT003 MDI",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Fumarate 12 μg (Foradil® Aerolizer®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 237,
      "start_date": "2011-05",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2017-01-31",
      "last_synced_at": "2026-10-10T01:04:23.317Z",
      "location_count": 10,
      "location_summary": "Glendale, Arizona • Fullerton, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349803"
    },
    {
      "nct_id": "NCT02091986",
      "title": "A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Symbicort pMDI",
          "type": "DRUG"
        },
        {
          "name": "Budesonide pMDI",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 882,
      "start_date": "2014-04",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-04-10",
      "last_synced_at": "2026-10-10T01:04:23.317Z",
      "location_count": 59,
      "location_summary": "Hoover, Alabama • Montgomery, Alabama • Gilbert, Arizona + 56 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02091986"
    },
    {
      "nct_id": "NCT00702325",
      "title": "Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Budesonide / formoterol fumarate (SYMBICORT)",
          "type": "DRUG"
        },
        {
          "name": "Budesonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 311,
      "start_date": "2008-06",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2012-11-09",
      "last_synced_at": "2026-10-10T01:04:23.317Z",
      "location_count": 57,
      "location_summary": "Pell City, Alabama • Bentonville, Arkansas • Hot Springs, Arkansas + 54 more",
      "locations": [
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Malvern",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00702325"
    },
    {
      "nct_id": "NCT01437540",
      "title": "Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Aclidinium Bromide/Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2011-09-19",
      "completion_date": "2013-04-30",
      "has_results": true,
      "last_update_posted_date": "2017-05-11",
      "last_synced_at": "2026-10-10T01:04:23.317Z",
      "location_count": 137,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 110 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01437540"
    },
    {
      "nct_id": "NCT05573464",
      "title": "A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "BGF MDI HFO 320/14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BGF MDI HFA 320/14.4/9.6 μg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 559,
      "start_date": "2022-09-27",
      "completion_date": "2024-03-26",
      "has_results": true,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-10-10T01:04:23.317Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Newport Beach, California • Miami, Florida + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05573464"
    },
    {
      "nct_id": "NCT05755906",
      "title": "A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "BFF MDI 160/9.6 μg BID (320/19.2μg/day)",
          "type": "DRUG"
        },
        {
          "name": "BD MDI 160 μg BID (320 μg/day)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 374,
      "start_date": "2023-02-27",
      "completion_date": "2024-11-19",
      "has_results": true,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-10-10T01:04:23.317Z",
      "location_count": 63,
      "location_summary": "Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 54 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755906"
    },
    {
      "nct_id": "NCT01360021",
      "title": "New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Symbicort",
          "type": "DRUG"
        },
        {
          "name": "Budesonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2011-11",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-03-11",
      "last_synced_at": "2026-10-10T01:04:23.317Z",
      "location_count": 31,
      "location_summary": "Huntington Beach, California • Long Beach, California • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01360021"
    }
  ]
}